Coherus Biosciences Inc  

(Public, NASDAQ:CHRS)   Watch this stock  
Find more results for CHRS
14.33
+1.09 (8.23%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.35 - 15.28
52 week 12.17 - 38.10
Open 13.48
Vol / Avg. 0.00/329,117.00
Mkt cap 603.21M
P/E     -
Div/yield     -
EPS -8.20
Shares 38.89M
Beta     -
Inst. own 58%
Mar 21, 2016
Q4 2015 Coherus BioSciences Inc Earnings Release (Estimated) Add to calendar
Jan 11, 2016
Coherus BioSciences Inc at JPMorgan Healthcare Conference
Dec 8, 2015
Coherus Biosciences Inc Reports Update to CHS-1701 Program - Webcast
Nov 18, 2015
Coherus BioSciences Inc at Jefferies Autumn Global Healthcare Conference
Nov 10, 2015
Coherus BioSciences Inc at Credit Suisse Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -997.42% -280.26%
Operating margin -993.68% -207.94%
EBITD margin - -205.77%
Return on average assets -126.91% -74.30%
Return on average equity -416.72% -
Employees 107 -
CDP Score - -

Address

201 Redwood Shores Pkwy Ste 200
REDWOOD CITY, CA 94065-1181
United States - Map
+1-650-6493530 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company focused on the global biosimilar market. The Company's clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor (TNF), and a long-acting form of granulocyte colony-stimulating factor (G-CSF). The Company's product pipeline includes anti-TNF product candidate, CHS-0214, an etanercept (Enbrel) biosimilar candidate which is in Phase III clinical trials, and anti-TNF product candidate, CHS-1420, an adalimumab (Humira) biosimilar candidate which is in Phase III clinical trials. The Company also offers G-CSF product candidate, CHS-1701, a pegfilgrastim (Neulasta) biosimilar which has completed a Phase I study.

Officers and directors

James M. Daly Executive Chairman of the Board
Bio & Compensation  - Reuters
Dennis M. Lanfear President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Jean-Frederic Viret Ph.D. Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Peter K. Watler Chief Technology Officer
Age: 53
Bio & Compensation  - Reuters
Alan C. Herman Ph.D. Chief Scientific Officer
Age: 67
Bio & Compensation  - Reuters
Barbara K. Finck M.D. Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Christos Richards Director
Age: 57
Bio & Compensation  - Reuters
August J. Troendle M.D. Director
Age: 58
Bio & Compensation  - Reuters
James I. Healy M.D., Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
V. Bryan Lawlis Jr., Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters